Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06130384 · ClinicalTrials.gov registry record · Phase 4
Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.
A Phase 4 study, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 4
- Development phase
- 97
- Enrollment target
NCT06130384: Completed Phase 4 study, sponsored by Wills Eye.
NCT06130384 is a Phase 4 study that has completed, run by Wills Eye. The registered enrollment target is 97 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06130384, a Phase 4 study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 97 participants
- Enrollment target
Study Summary
The purpose of this prospective interventional study is to compare post-intravitreal injection pain between eyes receiving topical bromfenac versus artificial tears as an analgesic after intravitreal injection.
Primary Outcome
Patients will be asked to report their pain on the Short Form McGill Questionnaire Present Pain Intensity score, ranging from 0 to 5, in which 5 is the worst pain level.
Interventions
- DRUG Use of bromfenac 0.09% to reduce intravitreal injection pain
- DRUG Use of artificial tears to reduce intravitreal injection pain
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2023-11-15 |
| Phase | Phase 4 |
What the finished NCT06130384 record still lists
NCT06130384 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Use of bromfenac 0.09% to reduce intravitreal injection pain is the first listed.
NCT06130384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06130384 about?
NCT06130384 is a clinical study titled "Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.". The purpose of this prospective interventional study is to compare post-intravitreal injection pain between eyes receiving topical bromfenac versus artificial tears as an analgesic after intravitreal injection.
What is the current status of trial NCT06130384?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 97 participants. The study started on 2021-03-01. Estimated completion is 2023-11-15.
What interventions are being tested in trial NCT06130384?
The interventions under investigation include: Use of bromfenac 0.09% to reduce intravitreal injection pain (DRUG), Use of artificial tears to reduce intravitreal injection pain (DRUG).
Who is sponsoring clinical trial NCT06130384?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06130384's enrollment target sits among peer trials
97 861st of 2000 higher than 1,138 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI